High Grade NENs

This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Watch Session A here: https://youtu.be/owZRDf3ISM4 Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org.

Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. For more information, visit LACNETS.org.

ABOUT THIS EPISODE What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. MEET DR. NITYA RAJ Nitya Raj, MD is a gastrointestinal medical oncologist with a clinical practice devoted to caring for people with gastrointestinal and endocrine cancers, including neuroendocrine tumors, adrenal cancer, colorectal cancer, pancreatic cancer, and other gastrointestinal cancers. Dr. Raj’s research focuses on advancing treatments for neuroendocrine cancers (a rare group of tumors that often begin in the body’s digestive organs as well as adrenocortical cancers. Dr. Raj is also studying ways to improve our understanding of how neuroendocrine tumors change at the genetic level over time and as a result of different treatments, in order to better personalize our care for people with these cancers. Dr. Raj’s work has been recognized and supported by the American Society of Clinical Oncology with a Young Investigator Award and Career Development Award, as well as by the Neuroendocrine Tumor Research Foundation with a Pilot Award. Nationally, Dr. Raj serves on the Neuroendocrine Tumor Task Force of the National Cancer Institute. Dr. Raj is on the faculty of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. TOP 10 QUESTIONS 1. What is a poorly differentiated grade 3 neuroendocrine carcinoma (NEC)? Are all NEC poorly differentiated and are all poorly differentiated NEC? Where are they located? 2. How are NEC found? How does one know it is a NEC? 3. How is NEC unique compared to other types of neuroendocrine cancers? In particular, how is it different from grade 3 NET? 4. What types of labs, scans, or testing for NEC? 5. Can a NEC be surgically removed? How would you decide if, when, and how? 6. How are NEC treated medically (or nonsurgically)? 7. What treatment might you use as second-line? What is the role of liver-directed therapy? What is the role of immunotherapy? 8. What are clinical trials we should be aware of or exciting new treatments in the pipeline for NEC? 9. How are NEC monitored? What types of bloodwork or tests should be done and how often should they be done? 10. What words of hope would you like to leave the neuroendocrine cancer community with? For more information, visit https://www.lacnets.org/podcast/25.

ABOUT THIS EPISODE What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. MEET DR. MOHAMAD BASSAM SONBOL Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis. TOP 10 QUESTIONS 1) What are grade 3 NETs? Where are they located? How is grade 3 NETs different from other types of NETs? In particular, how is it different from grade 3 NEC? Can NET change into NEC? 2) How are grade 3 NETs found? How does one know it is grade 3? 3) What types of labs, scans, or testing is done to determine if someone has a grade 3 NET? 4) Can a grade 3 NET be surgically removed? How would you decide if, when, and how? 5) How are grade 3 NETs treated medically (or nonsurgically)? How are treatments sequenced? 6) How are the treatments different from other NETs? 7) How are grade 3 NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for grade 3 NETs? 8) Can the tumors change in grade, Ki-67, and differentiation? What is the likelihood of NET changing to NEC and is there anything that can predict this or prevent this from happening? 9) What are clinical trials we should be aware of or exciting new treatments in the pipeline for grade 3 NETs? 10) What words of hope would you like to leave the NET community with? For more information, visit https://www.lacnets.org/podcast/24.

Join LACNETS on May 4th for an educational event dedicated to high grade neuroendocrine neoplasms (NENs). Medical oncologist Dr. Jason Starr from Mayo Clinic in Jacksonville, Florida, will discuss the management and treatment of high grade NENs, including the latest updates and clinical trials. For more information, visit LACNETS.org.

NET expert Dr. Aman Chauhan provides an update on high grade neuroendocrine tumors and treatment decisions. *The information of this presentation is valid as of March 2022. To download a copy of Dr. Chauhan's presentation slides, go to bit.ly/slides_march2022 Speaker: Aman Chauhan, MD, Medical Oncologist, University of Kentucky's Markey Cancer Center High grade NETs resources can be found here: lacnets.org/high-grade-nets-resources To learn more about LACNETS, visit www.LACNETS.org.

A patient living and thriving with high grade neuroendocrine cancer shares her inspiring story. This video was recorded in March 2022. High grade NETs resources can be found here: lacnets.org/high-grade-nets-resources To learn more about LACNETS, visit www.LACNETS.org.

NET Patient Cindy shares about living with high grade neuroendocrine cancer. November 17, 2020 To learn more about LACNETS, visit www.LACNETS.org.

Webinar: Focus on Immunotherapy & High-Grade NETs with Dr. Neena Vijayvergia Recorded on November 17th, 2020 Speaker: Neena Vijayvergia, MD, Hematology/Oncology, Fox Chase Cancer Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com